Entrada Therapeutics (NASDAQ:TRDA) Trading Up 1.1% – Should You Buy?

Entrada Therapeutics, Inc. (NASDAQ:TRDA)’s stock price rose 1.1% during mid-day trading on Thursday . The company traded as high as $7.49 and last traded at $7.40. 603,163 shares were traded during mid-day trading, an increase of 96% from the average session volume of 308,410 shares. The stock had previously closed at $7.32.

Analyst Upgrades and Downgrades

TRDA has been the subject of a number of recent analyst reports. HC Wainwright cut shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Oppenheimer boosted their price objective on Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a research report on Monday, April 6th. Weiss Ratings lowered Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Wall Street Zen lowered Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Guggenheim reduced their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $17.50.

Entrada Therapeutics Stock Down 6.5%

The company’s 50-day moving average is $7.36 and its 200-day moving average is $10.25. The stock has a market cap of $268.63 million, a price-to-earnings ratio of -1.73 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.11. The business had revenue of $0.88 million during the quarter, compared to analysts’ expectations of $2.92 million. Entrada Therapeutics had a negative return on equity of 51.22% and a negative net margin of 2,895.05%. On average, research analysts forecast that Entrada Therapeutics, Inc. will post -4.12 earnings per share for the current year.

Insider Activity

In other Entrada Therapeutics news, Director Bernhardt G. Zeiher purchased 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $5.86 per share, with a total value of $29,300.00. Following the completion of the acquisition, the director directly owned 5,000 shares of the company’s stock, valued at $29,300. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Nathan J. Dowden sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $15.33, for a total transaction of $229,950.00. Following the transaction, the chief operating officer owned 198,588 shares in the company, valued at $3,044,354.04. The trade was a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.49% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC increased its holdings in Entrada Therapeutics by 9.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after purchasing an additional 1,560 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Entrada Therapeutics by 7.1% during the third quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock worth $141,000 after buying an additional 1,620 shares during the last quarter. Great Lakes Advisors LLC boosted its holdings in Entrada Therapeutics by 5.5% during the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock worth $445,000 after buying an additional 2,239 shares during the last quarter. Quadrature Capital Ltd grew its position in shares of Entrada Therapeutics by 13.5% during the 4th quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock worth $209,000 after buying an additional 2,424 shares during the period. Finally, First Trust Advisors LP grew its position in shares of Entrada Therapeutics by 3.6% during the 2nd quarter. First Trust Advisors LP now owns 75,120 shares of the company’s stock worth $505,000 after buying an additional 2,631 shares during the period. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.